The ambition of Vrije Universiteit Amsterdam is clear: to contribute to a better world through outstanding education and ground-breaking research. And to be a university where personal education and societal involvement play a leading role. Where people from different disciplines and backgrounds work together on innovations and on generating new knowledge. Our teaching and research embrace the whole spectrum of science – from the humanities, the social sciences and the pure sciences through to the life sciences and the medical sciences.
Vrije Universiteit Amsterdam is home to more than 26,500 students. We employ more than 4,600 individuals. The VU campus is easily accessible, located in the heart of Amsterdam’s Zuidas district, a truly inspiring environment for teaching and research.Diversity
Diversity is one of our university’s core values. We are an inclusive community, and we believe that diversity and international activities enhance the quality of education and research. We are always looking for people who can enhance diversity on our campus thanks to their background and experience.School of Business and Economics
The School of Business and Economics (SBE) provides high-quality education and excellent research in business administration and economics with a focus on contributing to the social, economic and ecological challenges of our time. Whether it is the use of robots in society or big data, labour market participation or flexibility in the labour market, traffic jams or the housing market, flash crashes in the stock market or choice behaviour in gambling, leadership or change management: we believe in goal-oriented scientific research and understand that progress in academics, the business community and society is achieved through cooperation, openness and social responsibility.
At SBE, all of our highly-motivated colleagues work together closely in a stimulating, dynamic and international environment to achieve our collective goal of encouraging society to make informed choices. Approximately 4,200 Bachelor’s and Master’s students and 1,700 executive students are enrolled at the School, and employs roughly 500 people. About the KIN Center for Digital Innovation
The KIN Center for Digital Innovation
is one of the departments of the School of Business and Economics at the Vrije Universiteit Amsterdam. The KIN Center conducts research on the development, use and business value of innovative organizational processes and technologies. The research contributes to an international field that is relatively new and multi-disciplinary. We work closely together with faculty and researchers from other universities, and cooperate with an extensive network of business partners. The KIN Center for Digital Innovation is also responsible for several courses in the Business Administration curriculum at the Vrije Universiteit Amsterdam, and facilitates the Master Digital Business and Innovation.About the MIRIADE project
The project is being pursued in the framework of the Marie Skłodowska-Curie Innovative Training Network MIRIADE
(Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis). The overarching goal of the MIRIADE project is to train a novel generation of scientists able to accelerate dementia biomarker development. MIRIADE comprises of ten world-leading research organisations, 5 small to large industries and 2 patients organisations, from 12 countries in the EU, South-Korea and USA. A total of 15 Early Stage Researchers (ESRs) will be hosted across the network. The project will leverage existing proteomics datasets to identify the most promising candidate biomarkers for the major forms of dementias. It will develop an openly accessible integrated data platform for biomarker development (ESR1). ESR project 2 will focus on the prediction of protein-antibody interactions success in biomarker assay development. ESR3 will characterise protein surface accessiblility states in specific biological matrices, to improve biomarker assay development. ESR4-6 will develop specific reaction monitoring assays and validate these in CSF and blood of patients with AD (ESR4), FTD (ESR5) or DLB(ESR6). ESR7-10 will develop novel immunoassays in CSF and blood for all dementias (ESR7); AD (ESR8), FTD (ESR9) or DLB (ESR10). ESR11 and 12 will focus on the market-ready development of plasma abeta42 and abeta40 assays (ESR11) or neurofilament light (ESR12). ESR13 will develop reference methods for SRM assays for amyloid and neurofilament light CSF and blood assays. ESR14 and 15 will focus on innovation of the process, in order to generate a roadmap for efficient biomarker development. ESR14 will study how data are organized, shared, reused and integrated in academia and ESR15 will compare and evaluate different workflows of biomarker development.